Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Korábbi kezelés

• Symptomatic hypotension or systolic blood pressure less than 90mmHg after discontinuing intravenous medication
• Patients planning to undergo elective surgical treatment or tumor chemotherapy
• Previous diagnosis of cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, etc.

Más betegség

• Severe and uncontrolled lung diseases, such as newly developed pulmonary embolism, primary pulmonary hypertension, acute exacerbation of COPD, etc
• Allergies to ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA, Vericiguat, and other medications
• Diagnosed as Takotsubo cardiomyopathy or nonobstructive acute myocardial infarction (MINOCA)
• Autoimmune disease or infectious diseases with typical cardiovascular damage, such as syphilis, systemic lupus erythematosus, etc.
• Diagnosed with severe heart valve disease

Laborértékek

• Severe liver and kidney dysfunction, Child Pugh grade C or eGFR < 15ml/min/1.73m2

Egyéb

• Plan to undergo staged revascularization or if the criminal coronary artery has not been successfully opened
• Women in the perinatal period or those planning to conceive

• Age ≥ 18 years old
• Undertaking revascularization for criminal coronary artery during hospitalization
• Acute heart failure occurs within 14 days in hospital after STEMI or NSTEMI, meeting all of the following criteria: typical symptoms or signs of heart failure; Treatment with oral or intravenous diuretics is required; LVEF measured by echocardiography is ≤ 45%; Elevated levels of NT proBNP in patients with sinus rhythm ≥ 1000pg/ml and atrial fibrillation/flutter ≥ 1600pg/ml
• eGFR ≥ 15 ml/min/1.73m2
• Informed consent has to be given in written form